Literature DB >> 11509193

Different effects of anxiolytic agents, diazepam and 5-HT(1A) agonist tandospirone, on hippocampal long-term potentiation in vivo.

K Mori1, H Togashi, T Kojima, M Matsumoto, S Ohashi, K Ueno, M Yoshioka.   

Abstract

Benzodiazepines and 5-HT(1A) agonists have been widely used as anxiolytic agents. Some clinical reports document that 5-HT(1A) agonists induce memory impairment to a lesser degree than diazepam. In the present study, we compared the effects of diazepam and 5-HT(1A) agonist, tandospirone, on hippocampal long-term potentiation (LTP) in Schaffer collateral-CA1, mossy fiber-CA3 and perforant path-dentate gyrus synapses. In the diazepam-injected group, the reduction in LTP was observed in all three types of synapses, although the effective dose differed among these. In the tandospirone-injected group, no reduction in LTP was observed except in Schaffer-CA1 synapses. In addition, population spike amplitude was potentiated by tandospirone in mossy fiber-CA3 synapses in a dose-dependent manner. Thus, there was a discrepancy in the effects on hippocampal LTP between diazepam and tandospirone, possibly reflecting the reported clinical properties of these drugs, in that 5-HT(1A) partial agonists do not affect learning and memory, whereas diazepam impairs memory function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509193     DOI: 10.1016/s0091-3057(01)00546-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  16 in total

1.  Chronic treatment with milnacipran reverses the impairment of synaptic plasticity induced by conditioned fear stress.

Authors:  Machiko Matsumoto; Kaori Tachibana; Hiroko Togashi; Kazue Tahara; Taku Kojima; Taku Yamaguchi; Mitsuhiro Yoshioka
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

Review 2.  Characteristics of the functioning of the hippocampal formation in waking and paradoxical sleep.

Authors:  I G Sil'kis
Journal:  Neurosci Behav Physiol       Date:  2009-06-11

Review 3.  The role of serotonin in memory: interactions with neurotransmitters and downstream signaling.

Authors:  Mohammad Seyedabadi; Gohar Fakhfouri; Vahid Ramezani; Shahram Ejtemaei Mehr; Reza Rahimian
Journal:  Exp Brain Res       Date:  2014-01-16       Impact factor: 1.972

4.  Improvements in hippocampal-dependent learning and decremental attention in 5-HT(3) receptor overexpressing mice.

Authors:  Amber V Harrell; Andrea M Allan
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

5.  Chronic Enhancement of Serotonin Facilitates Excitatory Transcranial Direct Current Stimulation-Induced Neuroplasticity.

Authors:  Hsiao-I Kuo; Walter Paulus; Giorgi Batsikadze; Asif Jamil; Min-Fang Kuo; Michael A Nitsche
Journal:  Neuropsychopharmacology       Date:  2015-09-02       Impact factor: 7.853

6.  Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex.

Authors:  Giorgi Batsikadze; Walter Paulus; Min-Fang Kuo; Michael A Nitsche
Journal:  Neuropsychopharmacology       Date:  2013-05-17       Impact factor: 7.853

Review 7.  Review of targeted treatments in fragile X syndrome.

Authors:  Andrew Ligsay; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2016-08

Review 8.  The pharmacology of neuroplasticity induced by non-invasive brain stimulation: building models for the clinical use of CNS active drugs.

Authors:  Michael A Nitsche; Florian Müller-Dahlhaus; Walter Paulus; Ulf Ziemann
Journal:  J Physiol       Date:  2012-08-06       Impact factor: 5.182

Review 9.  Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

Authors:  Pau Celada; Analía Bortolozzi; Francesc Artigas
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

10.  D1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs.

Authors:  Michael Stramiello; John J Wagner
Journal:  Neuropharmacology       Date:  2008-07-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.